ArticleRadiology2018
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology.
Open access · hybridAbstract readComparative Study
In one paragraph
Article in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Phase-Sensitive Modeling Improves Fat DESPOT Multiparametric Relaxation Mapping in Fat-Water Mixtures.Magnetic resonance in medicine · 2026Article
- Oxygen-enhanced MRI in patients with uterine cervical carcinoma: feasibility and treatment-associated changes in tumour oxygen-enhanced response.Frontiers in oncology · 2026Article
- Adaptation mechanisms in cancer: Lipid metabolism under hypoxia and nutrient deprivation as a target for novel therapeutic strategies (Review).Molecular medicine reports · 2025Review
- Imaging hypoxia for head and neck cancer: current status, challenges, and prospects.Theranostics · 2025Review
- Oxygen-Enhanced MRI Detects Incidence, Onset, and Heterogeneity of Radiation-Induced Hypoxia Modification in HPV-Associated Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.Cancer research communications · 2024Article
- Oxygen-enhanced MRI assessment of tumour hypoxia in head and neck cancer is feasible and well tolerated in the clinical setting.European radiology experimental · 2024Observational
- Investigation of clear cell renal cell carcinoma grades using diffusion-relaxation correlation spectroscopic imaging with optimized spatial-spectrum analysis.The British journal of radiology · 2024Article
- Lipid droplets: a candidate new research field for epithelial ovarian cancer.Frontiers in pharmacology · 2024Article
- Functional Imaging of Hypoxia: PET and MRI.Cancers · 2023Review
- TThe British journal of radiology · 2023Article
- Oxygen-enhanced MRI and radiotherapy in patients with oropharyngeal squamous cell carcinoma.Clinical and translational radiation oncology · 2023Article
- Modeling the Effect of Hyperoxia on the Spin-Lattice Relaxation Rate R1 of Tissues.Magnetic resonance in medicine · 2022Article
- Article
- Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies.Biomaterials research · 2022Review
- Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.Cancer science · 2022Article
- A simplified empirical model to estimate oxygen relaxivity at different magnetic fields.NMR in biomedicine · 2022Article
- Article
- Oxygen-Sensitive MRI: A Predictive Imaging Biomarker for Tumor Radiation Response?International journal of radiation oncology, biology, physics · 2021Article
- Hypoxia and its therapeutic possibilities in paediatric cancers.British journal of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 2 countries.
Ross A LittleFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Yann JaminFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Jessica K R BoultFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Josephine H NaishFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Yvonne WatsonFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Susan CheungFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Katherine F HollidayFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Huiqi LuFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Damien J McHughFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Joely IrlamFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Catharine M L WestFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Guy N BettsFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Garry AshtonFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Andrew R ReynoldsFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Satish MaddineniFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Noel W ClarkeFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Geoff J M ParkerFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
John C WatertonFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
Simon P RobinsonFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
James P B O'ConnorFrom the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, England (Y.J., J.K.R.B., S.P.R.); Department of Pathology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England (G.N.B.); Department of Histology, CRUK Manchester Institute, Manchester, England (G.A.); Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, England (A.R.R.); Department of Urology, Salford Royal Hospitals NHS Foundation Trust, Salford, England (S.M., N.W.C.); Bioxydyn Ltd, Manchester, England (G.J.M.P., J.C.W.); and Department of Radiology, The Christie NHS Foundation Trust, Manchester, England (J.P.B.O.).
University of Manchester · GBInstitute of Cancer Research · GBAbsynth Biologics (United Kingdom) · GBBreast Cancer Now · GBManchester University · USSalford Royal Hospital · GBThe Christie NHS Foundation Trust · GB
Funding
Cancer Research UK 15267Cancer Research UK 16464Cancer Research UK 16465Cancer Research UK 22746Cancer Research UK C1060/10334Cancer Research UK C1090/A10334Cancer Research UK C1090/A16464Cancer Research UK C19221/A15267Cancer Research UK C19221/A22746Cancer Research UK C8742/A18097Wellcome TrustWellcome Trust 091763Z/10/Z
Abstract
Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. Materials and Methods Preclinical studies in nine 786-0-R renal cell carcinoma (RCC) xenografts and prospective clinical studies in eight patients with RCC were performed. Longitudinal relaxation rate changes (∆R1) after 100% oxygen inhalation were quantified, reflecting the paramagnetic effect on tissue protons because of the presence of molecular oxygen. Native transverse relaxation rate (R2*) and oxygen-induced R2* change (∆R2*) were measured, reflecting presence of deoxygenated hemoglobin molecules. Median and voxel-wise values of ∆R1 were compared with values of R2* and ∆R2*. Tumor regions with dynamic contrast agent-enhanced MRI perfusion, refractory to signal change at OE MRI (referred to as perfused Oxy-R), were distinguished from perfused oxygen-enhancing (perfused Oxy-E) and nonperfused regions. R2* and ∆R2* values in each tumor subregion were compared by using one-way analysis of variance. Results Tumor-wise and voxel-wise ∆R1 and ∆R2* comparisons did not show correlative relationships. In xenografts, parcellation analysis revealed that perfused Oxy-R regions had faster native R2* (102.4 sec
Indexed as
AdultAgedAnimalsBiomarkersCarcinoma, Renal CellDisease Models, AnimalFeasibility StudiesFemaleHumansHypoxiaImage EnhancementKidneyKidney NeoplasmsMagnetic Resonance ImagingMaleMiceBiomarkersOxygen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.